BioLife Solutions (BLFS) Stock Price
BioLife Solutions Price
Revenue has compounded at 30.6% per year over the past 19 years to 96.21 M USD. BioLife Solutions's net margin stands at -12.6%, down from -7.5% several years earlier. Analysts set a median price target of 32.64 USD, implying 10.7% below the current price. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus. The stock trades about 101% above its 52-week low.
BioLife Solutions stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BioLife Solutions over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioLife Solutions stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioLife Solutions's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BioLife Solutions Price |
|---|---|
| 8/28/2026 | 36.56 USD |
| 8/27/2026 | 37.17 USD |
| 8/26/2026 | 37.00 USD |
| 8/25/2026 | 37.22 USD |
| 8/24/2026 | 37.19 USD |
| 8/21/2026 | 37.10 USD |
| 8/20/2026 | 36.97 USD |
| 8/19/2026 | 36.21 USD |
| 8/18/2026 | 34.92 USD |
| 8/14/2026 | 35.07 USD |
| 8/13/2026 | 35.23 USD |
| 8/12/2026 | 34.97 USD |
| 8/11/2026 | 34.82 USD |
| 8/10/2026 | 34.64 USD |
| 8/7/2026 | 34.66 USD |
| 8/6/2026 | 33.93 USD |
| 8/5/2026 | 33.35 USD |
| 8/4/2026 | 32.05 USD |
| 8/3/2026 | 32.15 USD |
| 7/31/2026 | 31.28 USD |
| 7/30/2026 | 31.64 USD |
| 7/29/2026 | 31.79 USD |
| 7/27/2026 | 30.05 USD |
| 7/23/2026 | 30.77 USD |
| 7/22/2026 | 31.15 USD |
| 7/21/2026 | 29.19 USD |
| 7/20/2026 | 29.09 USD |
| 7/17/2026 | 29.15 USD |
| 7/16/2026 | 30.26 USD |
| 7/15/2026 | 29.15 USD |
BioLife Solutions Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLife Solutions Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.00 | 8.00 | 11.00 | 19.00 | 27.00 | 48.00 | 119.00 | 76.00 | 68.00 | 82.00 | 96.00 | 114.00 | 134.00 | 165.00 | 199.00 | 240.00 |
| – | 33.33 | 37.50 | 72.73 | 42.11 | 77.78 | 147.92 | -36.13 | -10.53 | 20.59 | 17.07 | 18.75 | 17.54 | 23.13 | 20.61 | 20.60 |
| 50.00 | 50.00 | 54.55 | 68.42 | 66.67 | 56.25 | 23.53 | 60.53 | 60.29 | 64.63 | 64.58 | 64.58 | 64.58 | 64.58 | 64.58 | 64.58 |
| 3.00 | 4.00 | 6.00 | 13.00 | 18.00 | 27.00 | 28.00 | 46.00 | 41.00 | 53.00 | 62.00 | 73.63 | 86.54 | 106.56 | 128.52 | 155.00 |
| -5.00 | -7.00 | -1.00 | 3.00 | – | -3.00 | -35.00 | -5.00 | -70.00 | -7.00 | -1.00 | 35.00 | 18.00 | 49.00 | 73.00 | 102.00 |
| -83.33 | -87.50 | -9.09 | 15.79 | – | -6.25 | -29.41 | -6.58 | -102.94 | -8.54 | -1.04 | 30.70 | 13.43 | 29.70 | 36.68 | 42.50 |
| -4.00 | -6.00 | -2.00 | 3.00 | -1.00 | 2.00 | -8.00 | -139.00 | -66.00 | -20.00 | -12.00 | 28.00 | 14.00 | 40.00 | 61.00 | 85.00 |
| 33.33 | 50.00 | -66.67 | -250.00 | -133.33 | -300.00 | -500.00 | 1,637.50 | -52.52 | -69.70 | -40.00 | -333.33 | -50.00 | 185.71 | 52.50 | 39.34 |
| 12.30 | 12.80 | 13.74 | 23.73 | 22.89 | 32.96 | 41.68 | 42.79 | 44.82 | 48.03 | 48.65 | 48.65 | 48.65 | 48.65 | 48.65 | 48.65 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BioLife Solutions generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioLife Solutions retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioLife Solutions's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BioLife Solutions has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioLife Solutions's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BioLife Solutions stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLife Solutions Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLife Solutions business model & stock analysis
BioLife Solutions SWOT Analysis
Strengths
1. Strong product portfolio: BioLife Solutions Inc offers a diverse range of innovative biopreservation tools and services, which cater to the growing needs of the biotech and pharmaceutical industries.
2. Established reputation: The company has built a solid reputation for delivering high-quality, reliable products, ensuring customer satisfaction and loyalty.
3. Robust research and development: BioLife Solutions Inc invests heavily in R&D, allowing them to stay at the forefront of technological advancements and develop cutting-edge solutions for their customers.
Weaknesses
1. Dependence on a few key customers: The company relies heavily on a small number of customers for a significant portion of its revenue, making it vulnerable to any changes in their preferences or buying patterns.
2. Limited global presence: BioLife Solutions Inc primarily operates in North America, which restricts its market reach and potential growth opportunities in other geographical regions.
3. Relatively small market share: Despite being a leader in biopreservation solutions, the company faces intense competition from larger, more established players in the industry.
Opportunities
1. Growing biotech and pharmaceutical sectors: The increasing demand for biopreservation tools and services presents immense growth opportunities for BioLife Solutions Inc.
2. Expansion into international markets: Exploring and expanding operations in new geographical regions would help the company tap into untapped markets and increase its customer base.
3. Strategic partnerships and collaborations: Forming partnerships with other industry players or research institutions could enhance BioLife Solutions Inc's capabilities and open doors to new technologies and markets.
Threats
1. Competitive market landscape: The biopreservation industry is highly competitive, with numerous established and emerging players vying for market share, which could potentially impact BioLife Solutions Inc's growth and profitability.
2. Regulatory challenges: Changes in government regulations pertaining to biopreservation or concerns related to product safety can pose challenges and increase compliance costs for the company.
3. Economic uncertainties: Global economic fluctuations or downturns may affect the spending capacity of BioLife Solutions Inc's customers, potentially impacting their demand for biopreservation products and services.
BioLife Solutions Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLife Solutions Segments
BioLife Solutions Revenue by Segment
3 Years
5 Years
Max
Details
BioLife Solutions Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
BioLife Solutions historical P/E ratio, EBIT multiple, and P/S ratio
BioLife Solutions annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BioLife Solutions shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLife Solutions stock splits
Current BioLife Solutions forecasts and price targets in September 2026
Analyst Price Targets 2026BioLife Solutions Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/10/2026 | Downgrade | BuyHold | 72 | |
| 7/27/2026 | Downgrade | OverweightEqual Weight | 67 | |
| 7/23/2026 | Downgrade | BuyHold | 60 | |
| 7/23/2026 | Downgrade | BuyHold | 56 | |
| 7/22/2026 | Downgrade | BuyHold | – | |
| 7/22/2026 | Downgrade | BuyNeutral | – | |
| 12/29/2025 | Maintained | Buy | – | |
| 11/24/2025 | Maintained | Buy | – | |
| 8/8/2025 | Maintained | Buy | – | |
| 5/13/2025 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
BioLife Solutions Earnings Calls
BioLife Solutions Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/6/2026 | 0.03USD | - | 28.24 MUSD | - | 2026 Q2 |
| 5/7/2026 | 0.02USD | - | 26.18 MUSD | - | 2026 Q1 |
| 3/2/2026 | -0.02USD | - | 24.56 MUSD | - | 2025 Q4 |
| 8/7/2025 | -0.04USD | - | 24.18 MUSD | - | 2025 Q2 |
| 11/12/2024 | -0.09USD | - | 26.05 MUSD | - | 2024 Q3 |
| 5/8/2024 | -0.34USD | - | 30.78 MUSD | - | 2024 Q1 |
| 3/14/2024 | -0.35USD | - | 34.50 MUSD | - | 2023 Q4 |
| 11/7/2023 | -0.13USD | - | 50.98 MUSD | - | 2023 Q3 |
| 8/7/2023 | -0.15USD | - | 47.45 MUSD | - | 2023 Q2 |
| 5/8/2023 | -0.19USD | - | 44.77 MUSD | - | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the BioLife Solutions stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
BioLife Solutions shareholder structure
| % | Name |
|---|---|
13.62477% | |
12.77755% | |
12.47475% | |
12.47475% | |
11.30207% | |
10.84903% |
BioLife Solutions Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
39.20% | SEC ↗ | |
38.30% | SEC ↗ | |
31.40% | SEC ↗ | |
22.90% | SEC ↗ | |
13.50% | SEC ↗ | |
11.50% | SEC ↗ | |
9.70% | SEC ↗ | |
9.70% | SEC ↗ | |
9.70% | SEC ↗ | |
9.70% | SEC ↗ |
BioLife Solutions Executives and Management Board
13 members · avg. age 56 · 38 % women
Mr. Roderick de Greef (64)
Chairman of the Board, Chief Executive Officer · since 2000
7.05 M USD
Management
Mr. Troy Wichterman (40)
Chief Financial Officer
Dr. Aby Mathew (53)
Chief Scientific Officer, Executive Vice President
Ms. Karen Foster (65)
Chief Quality and Operations Officer
Mr. Todd Berard (56)
Chief Commercial Officer
Ms. Sarah Aebersold (51)
Chief Human Resources Officer
Dr. Sean Werner (51)
Chief Technology Officer
Board of Directors
Ms. Amy Duross (51)
Lead Independent Director
Mr. Joydeep Goswami (53)
Independent Director
Ms. Rachel Ellingson (55)
Independent Director
Mr. Timothy Moore (64)
Independent Director
Ms. Catherine Coste (59)
Independent Director
Mr. Tony Hunt (61)
Independent Director
BioLife Solutions Supply Chain
BioLife Solutions Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.82 | 0.82 | 0.77 | ||
| 2 | 0.97 | 0.79 | 0.57 | ||
| 3 | 0.86 | 0.81 | 0.43 | ||
| 4 | 0.88 | 0.37 | 0.39 | ||
| 5 | 0.82 | 0.12 | 0.31 |
Frequently asked questions about BioLife Solutions
BioLife Solutions Inc is a biotech company specializing in developing, manufacturing, and marketing cell and tissue preservation solutions. Their business model revolves around providing innovative products that enhance the effectiveness of biological materials storage and transportation. BioLife Solutions offers a comprehensive portfolio of biopreservation media, enabling improved cell therapies, vaccines, and drug discovery research. By supplying high-quality, proprietary products, BioLife Solutions caters to the needs of various sectors, including regenerative medicine, biobanking, and pharmaceuticals. Through their advanced technologies and solutions, BioLife Solutions Inc aims to support the success of customers in preserving and delivering vital biological materials.
BioLife Solutions Inc is primarily active in the biotechnology industry.
The main competitors of BioLife Solutions Inc in the market include companies such as Thermo Fisher Scientific Inc, Merck KGaA, Teva Pharmaceutical Industries Ltd, and Zimmer Biomet Holdings Inc.
BioLife Solutions Inc, a leading developer and supplier of biopreservation tools for cells and tissues, has a rich history and background. Founded in 1998, the company has been dedicated to improving the quality and extending the shelf life of biological materials. BioLife Solutions Inc specializes in innovative solutions that enable the effective storage, freezing, and transportation of biological samples used in research, clinical trials, and regenerative medicine. With a strong focus on quality and customer satisfaction, BioLife Solutions Inc has become a trusted partner for biotech and pharmaceutical companies worldwide. The company's commitment to continuous innovation and collaboration underscores its position as a leader in the biopreservation industry.
BioLife Solutions Inc. has accomplished several significant milestones. The company has expanded its product portfolio, offering a comprehensive range of innovative biopreservation solutions for cells, tissues, and organs. It has successfully developed and commercialized proprietary technologies to enhance the shelf life and improve the efficacy of biological materials. Furthermore, BioLife Solutions has achieved consistent revenue growth and profitability, demonstrating its strong market presence and customer satisfaction. The company has also forged strategic partnerships with leading organizations, leveraging its expertise to develop cutting-edge biopreservation systems. These achievements highlight BioLife Solutions Inc.'s commitment to advancing biological storage and transportation solutions while delivering value to its customers and stakeholders.
BioLife Solutions Inc is primarily present in the United States. With its headquarters located in Bothell, Washington, the company operates throughout the country. As a leading provider of biopreservation tools and services, BioLife Solutions Inc serves a diverse customer base in the life sciences industry across various states and regions in the United States. The company focuses on supplying innovative bioprocessing solutions and ensuring the quality and preservation of biological materials, such as cells, tissues, and organs, for medical research and therapeutic purposes.
BioLife Solutions Inc is a leading provider of biopreservation tools and services. The company's values center around innovation, quality, and customer satisfaction. With a strong commitment to advancing regenerative medicine and improving patient outcomes, BioLife Solutions Inc focuses on delivering best-in-class biopreservation solutions to its clients. The corporate philosophy of the company revolves around continuous improvement and collaboration with customers, researchers, and industry partners. By offering a wide range of high-performance biopreservation products and leveraging its expertise in cell and tissue preservation, BioLife Solutions Inc strives to contribute to the success and progress of the life sciences industry.
Analysts currently set an average price target of 32.87 USD for the BioLife Solutions stock (median: 32.64 USD), implying -7.3 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the BioLife Solutions stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BioLife Solutions to generate revenue of 114.65 M USD and earnings per share of 0.59 USD.
Converted at the current exchange rate, the BioLife Solutions share trades at 31.57 EUR (36.56 USD).
The BioLife Solutions share (BLFS) is listed on 3 stock exchanges, including: NASDAQ (BLFS), Frankfurt (BJX1.F), Düsseldorf (BJX1.DU).
BioLife Solutions Inc is a company specializing in the production of high-quality biological solutions for customers in the biopharmaceutical and biotechnology industries. The business is divided into two main divisions: BioLife Solutions and Astero Bio. BioLife Solutions focuses on manufacturing proprietary biological solutions for customers in the biopharmaceutical and biotechnology industries, which are used for the stabilization and maintenance of the quality of biological materials such as cells, tissues, and organs. Products include CryoStor, a clinically tested cell cryopreservation solution, and HypoThermosol, a patented cell culture medium specifically designed for the storage and transportation of cell and tissue samples. BioLife Solutions also offers custom formulations for specific applications. The second division, Astero Bio, specializes in the development and manufacturing of temperature control devices for biological storage. The Astero portfolio includes cryogenic storage systems that maintain the quality and integrity of biological samples during storage. Astero Bio also offers biological safety cabinets for laboratories handling pathogenic or toxin-producing organisms. BioLife Solutions and Astero Bio work together to provide their customers with a complete solution for the stabilization and protection of biological materials. The products and solutions of BioLife Solutions and Astero Bio are tailored to meet customer requirements and comply with international standards such as Good Manufacturing Practice (GMP) and the International Organization for Standardization (ISO). BioLife Solutions' business model is based on a value chain, starting with the research and development of new biological solutions and extending to the production and market introduction of these solutions. The solutions and products of BioLife Solutions and Astero Bio are designed to meet customer needs and aim to enhance the efficiency and profitability of companies in the biopharmaceutical and biotechnology industries. BioLife Solutions and Astero Bio have a strong position in the global market for biological solutions, and their products are used by leading companies and institutions worldwide. The company has a strong track record and is committed to further growth and expanding its technological capabilities in the future. The products and solutions of BioLife Solutions and Astero Bio contribute to the progress and development in biotechnology, ultimately improving the quality of life for patients worldwide.
The expected revenue of BioLife Solutions is 114.65 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioLife Solutions is 28.65 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioLife Solutions is currently 62.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioLife Solutions stock.
The price-to-sales ratio (P/S) of BioLife Solutions is currently 15.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioLife Solutions stock.
The Eulerpool Quality Score for BioLife Solutions is 2/10.
The ISIN of BioLife Solutions is US09062W2044. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioLife Solutions is A1XCF2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioLife Solutions is BLFS. The ticker symbol is used to trade BioLife Solutions shares on the stock exchange.
BioLife Solutions paid dividends every year for the past 0 years.
BioLife Solutions is assigned to the 'Health' sector.
The dividends of BioLife Solutions are distributed in USD.
BioLife Solutions stock
BioLife Solutions Peer Group
BioLife Solutions Ticker
BioLife Solutions FIGI
All fundamentals and in-depth analysis of BioLife Solutions
Our stock analysis for BioLife Solutions stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioLife Solutions. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.